enzh-TWfrdeitjaptrues

The Dana-Farber Bing Center for Waldenstrom's Macroglobulinemia Web site is intended to provide general information about the program, its care and research programs, and about Waldenstrom's Macroglobulinemia and related diseases. This site also provides links to health information that may be written by Dana-Farber staff or by outside providers, and access (links) to some external Web sites for your convenience. The Dana-Farber Waldenstrom's Macroglobulinemia Program is not responsible for the availability, accuracy, or content of these external sites, nor does it endorse them.

No Medical Advice Given
This site is not an attempt to practice medicine or provide specific medical advice, nor does the use of the site establish a doctor-patient relationship. For medical treatment or answers to personal questions, we strongly encourage you to consult with a qualified health care provider. For advice about your own care, please ask your doctor!

Restrictions on Use
You assume full responsibility for using the information on this site, and you understand and agree that the Dana-Farber Waldenstrom's Macroglobulinemia Program is not responsible or liable for any claim, loss, or damage resulting from its use. While we try to keep the information on the site as accurate as possible, we disclaim any warranty concerning its accuracy, timeliness, and completeness, and any other warranty, express or implied, including warranties of merchantability or fitness for a particular purpose. The Dana-Farber Waldenstrom's Macroglobulinemia Program also does not warrant that access to the site will be error- or virus-free.

Copyright Infringement
Material on the Dana-Farber Waldenstrom's Macroglobulinemia Program Web site is protected by copyright law. Unless otherwise stated, users may print or download information from this site for personal, non-commercial use only. Permission to reprint or otherwise reproduce any document in whole or in part is prohibited, unless prior written consent is obtained from the copyright owner.

Latest Bing Center News

International Patients

International Patients

Every year, thousands of people with cancer from around the world come to Dana-Farber for their care. If you live outside the US and wish to make an appointment at Dana-Farber Cancer Institute, please complete this online form or contact the appropriate person below:

Read more..

UPDATE: Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)

UPDATE: Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)

Workshop Date and Time: Wednesday, April 21, 2021, 12:30 – 1:30pm (EDT). AN AUDIO RECORDING IS NOW AVAILABLE! This will be the 8th collaboration between IWMF and CancerCare in a Connect® Education Workshop on WM. CancerCare, is the leading national organization in the U.S. providing free, professional support services and information to help people manage the emotional, practical and financial challenges of cancer.

Read more..

LLS Patient Education: Waldenstrom’s Macroglobulinemia Update

LLS Patient Education: Waldenstrom’s Macroglobulinemia Update

Please join LLS and Memorial Cancer Institute for a free virtual education program for patients and their families. Presenters will discuss the latest advances in Waldenstrom’s Macroglobulinemia from diagnosis to living with the disease.

Read more..

Ask the Doctors LIVE: WM and the COVID Vaccine

Ask the Doctors LIVE: WM and the COVID Vaccine

March 31, 2021 Webinar: Our IWMF experts will share an update on the status of existing vaccines and others in development. This interactive LIVE question and answer session will explain side effects and recommendations for WM patients.

Read more..

Treatment Advancements are Improving Survivorship and Prompting Hope

Treatment Advancements are Improving Survivorship and Prompting Hope

Is a cure for Waldenstrom macroglobulinemia on the horizon? In the past several decades Waldenstrom’s survivorship has vastly improved due to safer and more effective treatment drugs. Could this indicate that a cure might be within reach?

Read more..

New Treatment Options for Waldenstrom Macroglobulinemia

New Treatment Options for Waldenstrom Macroglobulinemia

New combination drug regimens are being studied for the treatment of Waldenstrom macroglobulinemia (WM). In this segment, Dr. Jorge Castillo, MD, of Dana-Farber Cancer Institute updates patients on the information presented at the recent American Society of Hematology (ASH) conference and suggests that Waldenstrom patients pay attention to the combination of ibrutinib and rituximab (INNOVATE Study), that have shown faster and deeper responses over time versus rituximab alone.

Read more..

A 70-year-old New Brunwick man to walk 300 kilometres for rare cancer awareness

A 70-year-old New Brunwick man to walk 300 kilometres for rare cancer awareness

A Rothesay man fighting a rare cancer is stepping up to raise awareness about the disease. And as Travis Fortnum reports, he’s planning a month-long walk to do it.

Read more..

2021 IWMF Global Educational Webinar with Dr. Stephen Ansell & Dr. Jorge Castillo

2021 IWMF Global Educational Webinar with Dr. Stephen Ansell & Dr. Jorge Castillo

Our IWMF experts will share an update on the status of existing COVID-19 vaccines and others in development. This interactive LIVE question and answer session will explain side effects and recommendations for WM patients.

Read more..

Clinical Trials Are Moving Out of the Lab and Into Peopleʼs Homes

Clinical Trials Are Moving Out of the Lab and Into Peopleʼs Homes

After the pandemic forced thousands of trials to shut down, researchers found clever ways to conduct human studies remotely — while reaching more people, quickly and cheaply.

Read more..